Pandemics from various viruses make natural organisms face challenges over and over
again. Therefore, new antiviral drugs urgently need to be found to solve this problem …

Background Respiratory syncytial virus (RSV) is the leading global cause of respiratory
infections and is responsible for about 3 million hospitalizations and more than 100,000 …

Introduction Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract
infection (LRTI)-related hospitalizations in older adults. Without RSV-specific treatment for …

Respiratory syncytial virus (RSV), a member of the Pneumoviridae family, can cause severe
acute lower respiratory tract infection in infants, young children, immunocompromised …

Along the line of recent vaccine advancements, new antiviral therapeutics are compelling to
combat viral infection‐related public health crises. Several properties of silver nanoparticles …

Background The emergence of the Severe Acute Respiratory Syndrome Coronavirus 2
(SARS‐CoV‐2) in early 2020 and subsequent implementation of public health and social …

Background Respiratory syncytial virus (RSV) is a major cause of acute lower respiratory
tract infection (ALRI) leading to infant hospitalization, morbidity and postnatal mortality in …

Respiratory syncytial virus (RSV) is a common cause of pulmonary infection among children
and has been increasingly recognized as an important respiratory pathogen in older adults …

In the adult population, community-acquired pneumonia (CAP) is a serious disease that is
responsible for high morbidity and mortality rates, being frequently associated with multidrug …

Respiratory syncytial virus (RSV) infection is increasingly recognized as a cause of
significant morbidity and mortality in adults. We aimed to estimate the rates of age-specific …